Daraxonrasib
Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors[1][2][3].
Product Specifications
CAS Number
2765081-21-6
Product Name Alternative
RMC-6236; RAS-IN-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PERK; Ras
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rmc-6236.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(COC([C@H]1NN(C([C@H](CC2=NC3=CS2)NC([C@H]4C[C@@H]4C)=O)=O)CCC1)=O)(C)CC5=[C@@](N(CC)C6=C5C=C3C=C6)[C@@]7=C([C@H](C)OC)N=CC(N8CCN(C)CC8)=C7
Molecular Formula
C44H58N8O5S
Molecular Weight
811.05
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
K-Ras
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
VEGF-A (VEGF/1063), CF568 conjugate, 0.1mg/mL
